Nov. 20 at 3:59 PM
$LEXX Why I think phase 2 is almost guaranteed at this point.
Lexaria’s DehydraTECH uses GRAS ingredients, standard manufacturing methods, and fits within familiar regulatory pathways like 505(b)(2), making it appealing for companies seeking better-tolerated or lower-dose oral GLP-1 formulations. The IP portfolio further strengthens its position. Although early data are encouraging, most results come from small human pilots and preclinical studies, so larger Phase 2 and 3 trials are needed to confirm benefits. Key upcoming milestones include full Phase 1b results, larger randomized studies, additional brain-delivery data, and potential commercial partnerships. Overall, DehydraTECH shows promise in improving oral absorption, reducing side effects, and enhancing brain exposure, but broader clinical validation will determine its true impact.
$NVO $PFE $LLY
